This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CHOP Collaborates With Pfizer's Centers For Therapeutic Innovation To Speed Pediatric Research & Development

PHILADELPHIA, April 3, 2013 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia (CHOP) and Pfizer, Inc., are joining forces with the goal of translating biomedical discoveries into novel treatments. CHOP is announcing its participation in the Centers for Therapeutic Innovation (CTI) network, a novel collaboration model built by Pfizer that brings academic researchers together with Pfizer scientists to expedite the pace of innovation.

Children's Hospital is only the second pediatric center to join the CTI network, which has established partnerships with 21 academic medical centers throughout the United States, such as Rockefeller University, Beth Israel Deaconess Medical Center, and the University of California, San Francisco.

"We are excited to have this opportunity to accelerate the process of moving scientific insights toward therapies that healthcare providers can offer in the clinic," said Philip R. Johnson, M.D., chief scientific officer and senior vice president of The Children's Hospital of Philadelphia. Johnson is one of CHOP's representatives on a joint steering committee with Pfizer representatives that will direct CTI's activities in Philadelphia.

CTI will bring together scientists from Pfizer and Children's Hospital to identify preclinical research at CHOP with potential applications for innovative treatments. Pfizer will share with CHOP researchers an extensive collection of antibodies and other proteins, along with other proprietary research and drug-development tools. CHOP investigators will collaborate with Pfizer scientists at CTI laboratories in both Boston and New York City.

The goal is to advance a project into a Phase 1 clinical trial.

"This partnership will bring together the leading science at The Children's Hospital of Philadelphia with Pfizer's global capabilities," said Jose Carlos Gutierrez-Ramos, Ph.D., senior vice president, Head of Biotherapeutics R&D at Pfizer. "Together, we increase the potential to bring novel medicines to patients."

A March 15 Town Hall at CHOP introduced CTI to the Hospital's researchers, who are being encouraged to submit concise proposals by April 15 for projects to be considered. In July 2013, the steering committee will choose projects for funding.

This expedited timetable is much faster than the typical schedule for federally sponsored research. In contrast to many partnerships between private industry and academia that focus on one highly defined end-product, CTI is designed to identify cutting-edge areas of research in areas of high unmet need that hold strong potential for therapeutic interventions.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs